Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O95528
UPID:
GTR10_HUMAN
Alternative names:
Glucose transporter type 10
Alternative UPACC:
O95528; A8K4J6; Q3MIX5; Q9H4I6
Background:
The Solute carrier family 2, facilitated glucose transporter member 10, also known as Glucose transporter type 10, plays a pivotal role in glucose transport essential for cardiovascular development. Its unique function underscores its importance in maintaining glucose homeostasis and supporting the cardiovascular system's structural integrity.
Therapeutic significance:
Arterial tortuosity syndrome, a severe disorder characterized by the deformation and elongation of major arteries, is linked to mutations in the gene encoding this transporter. Understanding the role of Solute carrier family 2, facilitated glucose transporter member 10, could open doors to potential therapeutic strategies for managing and potentially treating this life-threatening condition.